Brian Hyohyoung Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brian Hyohyoung Lee has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Seunghee Kim-Schulze
Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY
95 shared publications - Hyun Je Kim
Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea
81 shared publications - Miriam Merad
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA
77 shared publications - Yoon Ji Bang
Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea
77 shared publications - Chaeyeon Kim
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
76 shared publications - Chan-Young Ock
Lunit, Seoul, Republic of Korea
76 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (1) , 104-122
High-Dimensional Profiling of Circulating Dendritic Cells and Monocytes in Atopic Dermatitis Patients by Mass Cytometry
Jeong S, et al. Allergy Asthma Immunol Res. 2026 Jan;18(1):104-122. https://doi.org/10.4168/aair.2026.18.1.104
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (1) , 104-122
Open AccessHigh-Dimensional Profiling of Circulating Dendritic Cells and Monocytes in Atopic Dermatitis Patients by Mass Cytometry
Jeong S, et al. Allergy Asthma Immunol Res. 2026 Jan;18(1):104-122. https://doi.org/10.4168/aair.2026.18.1.104
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S18 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
High-dimensional profiling of regulatory CD4+ T cells.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S18 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
High-dimensional profiling of regulatory CD4+ T cells.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Dynamic changes in the composition of CD8+ T cells in response to the treatment administered.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Dynamic changes in the composition of CD8+ T cells in response to the treatment administered.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Reported trials on neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Reported trials on neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Baseline and treatment characteristics of patients treated with cytotoxic chemotherapy TS-1 (tegafur, gimeracil, and oteracil potassium) and cisplatin.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Baseline and treatment characteristics of patients treated with cytotoxic chemotherapy TS-1 (tegafur, gimeracil, and oteracil potassium) and cisplatin.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
High-dimensional profiling of CD8+ T cells.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
High-dimensional profiling of CD8+ T cells.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S19 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Dynamic changes in the composition of regulatory CD4+ T cells in response to the treatment administered.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S19 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Dynamic changes in the composition of regulatory CD4+ T cells in response to the treatment administered.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Enumerization of tumor-infiltrating T cells by immunohistochemostry stain.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Enumerization of tumor-infiltrating T cells by immunohistochemostry stain.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Tornado plot for immune-related adverse events.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Tornado plot for immune-related adverse events.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Representative immunofluorescence staining for tumor-infiltrating T cells. T cells were stained with CD8 (blue), CD4 (green), and FoxP3 (red).
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
Representative immunofluorescence staining for tumor-infiltrating T cells. T cells were stained with CD8 (blue), CD4 (green), and FoxP3 (red).